Bioventus (BVS) - 2023 Q3 - Quarterly Report

Cash, cash equivalents and restricted cash as of September 30, 2023 totaled $26.8 million, compared to$30.2 million as of December 31, 2022. The decrease in cash was primarily due to the following: Table of Contents TABLE OF CONTENTS As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to "Bioventus," "we," "us," "our," "the Company," and similar references refer to Bioventus Inc. and its consolidated subsidiaries, including Bioventus LLC ( ...